Details of the Drug Formulations

General Information of Drug (ID: DMND304)

Drug Name
Miltefosine Drug Info
Synonyms
HDPC; HePC; Hexadecylphosphocholine; Hexadecylphosphorylcholine; Impavido; Miltefosina; Miltefosinum; Miltex; Baxter Oncology brand of miltefosine; Baxter brand of miltefosine; Miltefosin C; Prasfarma brand of miltefosine; D 18506; IN1227; D-18506; H-1850; M-7200; Miltefosina [INN-Spanish]; Miltefosine (INN); Miltefosine[INN:BAN]; Miltefosinum [INN-Latin]; N-Hexadecylphosphorylcholine; TF-002; Choline hydroxide, hexadecyl hydrogen phosphate, inner salt; Choline, hexadecyl hydrogen phosphate, inner salt; Hexadecyl 2-(trimethylazaniumyl)ethyl phosphate; Choline phosphate, hexadecyl ester, hydroxide, inner salt; Choline phosphate, hexadecyl ester, hydroxide, inner salt (6CI); Hexadecyl 2-(trimethyl-.lambda.~5~-azanyl)ethyl hydrogen phosphate; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, inner salt; Ethanaminium, 2-(((hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethyl-, hydroxide, innner salt; 1-Hexadecylphosphorylcholine; 2-(((Hexadecyloxy)hydroxyphosphinyl)oxy)-N,N,N-trimethylethanaminium hydroxide, inner salt; 3,5-Dioxa-4-phosphaunacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-, hydroxide, inner salt, 4-oxide
Indication
Disease Entry ICD 11 Status REF
Chronic urticaria Approved [1]
Leishmaniasis 1F54 Approved [2]
Visceral leishmaniasis 1F54.0 Phase 2 [3]
Therapeutic Class
Antifungal Agents
Cross-matching ID
PubChem CID
3599
ChEBI ID
CHEBI:75283
CAS Number
58066-85-6
TTD ID
D00FGR
INTEDE ID
DR1092
ACDINA ID
D00436

Full List of Drug Formulations Containing This Drug

Miltefosine 50 mg capsule
Company Formulation ID FDA Description
Paladin Therapeutics F14078 Lactose monohydrate; Magnesium stearate; Ferric oxide red; Talc; Titanium dioxide; Water; Silicon dioxide; Cellulose, microcrystalline; Gelatin
Profounda F14079 Lactose monohydrate; Magnesium stearate; Ferric oxide red; Talc; Titanium dioxide; Water; Silicon dioxide; Gelatin, unspecified; Microcrystalline cellulose
------------------------------------------------------------------------------------

References

1 Miltefosine FDA Label
2 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3 Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22.